FUCHS-PETROLUB-SE
15.11.2021 10:02:05 CET | Business Wire | Press release
The FUCHS Group, which operates globally in the lubricants industry, brings new small packs for the automotive sector onto the market, maximizing customer benefits: new labels for better orientation, ergonomic design for better handling, and gentle on resources thanks to the use of recycled material. The new small packs will be implemented gradually in the FUCHS companies from November 15, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211115005059/en/
The range of lubricant products in the automotive sector is enormous – and for customers it's getting harder and harder to find what they need. The new small packs for all automotive FUCHS product brands – TITAN, AGRIFARM, MAINTAIN, PLANTO, and SILKOLENE – rise to this challenge: The Group has optimized its small packs globally for the quantities 1, 4, and 5 liters, not just visually but also in terms of handling and environmental friendliness. "The unique new design makes it easier for our customers to choose the right product, improves user-friendliness, and saves on resources," sums up Krisztián Rada, Head of Automotive Aftermarket Division.
Easy to choose
The new clearly structured design of the labels enables customers to identify all the relevant information at a glance. Colors, images, and pictograms help with orientation. For instance, the quality levels of the products are clearly indicated by the color codes gold, silver, and bronze. The most important information the customer needs to know about the lubricant is given in concise and comprehensible way, such as the viscosity of the product and area of application – for cars, trucks, or tractors.
Easy to use
The new ergonomically shaped bottles are easy to open without tools, fit better in the hand, and are easier for the user to handle. For example, the enlarged opening of the bottle and an optimized neck design allow accurate filling with no drops. Two handles make the 4 and 5-liter bottles more comfortable to carry and facilitate filling. What's more, the new tamper-resistant cap ensures that the bottle has not been opened before and that if FUCHS is written on it, there is FUCHS inside it.
Easy on the environment :
FUCHS has been pursuing its sustainability strategy for almost ten years now, with the objective of carbon neutrality according to the "avoid – reduce – compensate" principle. As such, all FUCHS lubricants in the Group's plants are produced carbon-neutrally. The bottle material of the new small packs consists of up to 30 percent recycled material (PCR) and is 100-percent recyclable. The improved bottle shape of the bottle also makes it possible to pour out even the smallest remaining volume of fluid, allowing complete emptying of the bottles. "Our new small packs are not just intended to be more user-friendly but also contribute to avoiding waste, enable materials to be recycled, and help to reduce carbon footprints. FUCHS will continue to work toward making our packaging continuously more sustainable in the future, too," says Markus Garb, Vice President Sustainability, stating a further objective of the innovation.
The following information material is available online:
About FUCHS
FUCHS develops, produces and markets high-grade lubricants and related specialties for virtually all industries and areas of application. The company, which was founded in Mannheim in 1931, employs around 6,000 people worldwide at 58 operating companies. FUCHS is the world's largest independent lubricant manufacturer. The most important markets in terms of sales revenue are Western Europe, Asia and North America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211115005059/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
